Glioblastoma trial readouts
registry pull 2026-08-19Primary-completion dates that listed drug and biotech companies filed with ClinicalTrials.gov for studies in Glioblastoma. They are the sponsor's own estimated windows, revised as a study runs — not announcement dates. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Upcoming readout windows
next 180 days · by month4 studies across 4 companies, in the next 180 days.
September 2026 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| AZN | AstraZeneca | A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain CancerNCT03423628Incidence of dose-limiting toxicities (DLTs) | Phase 1 | Active, not recruiting | 2026-09-03 | in 14 d | 2026-07-17 |
October 2026 2
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| BSX | Boston Scientific Corporation | A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBMNCT05303467The number of grade 3-5 non-hematological toxicities | Phase 1 | Recruiting | 2026-10-31 | in 72 d | 2026-07-31 |
| PHIL.MI | Philogen S.p.A. | Safety and Efficacy of L19TNF Plus Temozolomide Chemoradiotherapy in Patients With Newly Diagnosed GlioblastomaNCT04443010For Phase 1: DLT | Phase 1/2 | Recruiting | Oct 2026 | ≤ 72 d | 2023-10-10 |
December 2026 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| INO | Inovio Pharmaceuticals | INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM)NCT03491683Percentage of Participants with Adverse Events (AEs) | Phase 1/2 | Active, not recruiting | 2026-12-31 | in 133 d | 2026-05-04 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Every registered study in Glioblastoma
most recently updated first81 studies match.
| Ticker | Name | Market cap | Study | Phase | Status | Interventions | Conditions | Enrollment | Start | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BDTX | Black Diamond Therapeutics, Inc. | $118M | Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIIINCT07326566Progression-free survival (PFS) assessed by Blinded Independent Central Review (BICR) | Phase 2 | Recruiting | Drug: silevertinib in combination with temozolomide, temozolomide (TMZ) | Glioblastoma (GBM), Newly Diagnosed Glioblastoma, GBM, Glioblastoma Multiforme (GBM), Glioma, Central Nervous System Diseases, Brain Cancer | 162 | 2026-05-05 | Nov 2028 | ≤ 833 d | 2026-08-13 |
| BSX | Boston Scientific Corporation | $73.1B | A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBMNCT05303467The number of grade 3-5 non-hematological toxicities | Phase 1 | Recruiting | Device: TheraSphere GBM | Glioblastoma Multiforme, Recurrent Glioblastoma | 36 | 2022-07-30 | 2026-10-31 | in 72 d | 2026-07-31 |
| AZN | AstraZeneca | — | A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain CancerNCT03423628Incidence of dose-limiting toxicities (DLTs) | Phase 1 | Active, not recruiting | Radiation: Radiation Therapy, Radiation Therapy, Radiation Therapy · Drug: AZD1390, AZD1390, AZD1390 | Recurrent Glioblastoma Multiforme, Primary Glioblastoma Multiforme, Brain Neoplasms, Malignant, Leptomeningeal Disease (LMD) | 159 | 2018-04-02 | 2026-09-03 | in 14 d | 2026-07-17 |
| NTHI | Neonc Technologies, Inc. | $143M | Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated GliomaNCT02704858Phase 1 Primary Outcome: Number of Participants with Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment | Phase 1/2 | Active, not recruiting | Drug: Perillyl alcohol | Glioblastoma Multiforme | 49 | 2017-08-01 | 2026-07-30 | — | 2026-07-16 |
| IBRX | ImmunityBio, Inc. | $8.2B | N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive GlioblastomaNCT06061809Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) | Phase 2 | Active, not recruiting | Drug: Bevacizumab, PD-L1 t-haNK, N-803 · Device: Tumor Treating Fields (TTFields, 200 kHz) | Glioblastoma | 34 | 2024-08-07 | 2029-12-31 | in 1,229 d | 2026-07-01 |
| GNTA | Genenta Science | — | A Study Evaluating Temferon in Patients With Glioblastoma & Unmethylated MGMTNCT03866109Tolerability and safety of Temferon over the first 90 days following administration as determined by the incidence of adverse events | Phase 1/2 | Terminatedsponsor's stated reason: LVLP (pt GBM-01034) took place on 27may2026. The 2 remaining slots allocated by the protocol for the additional cohort to generate safety data prior to study Part B will not be filled. No safety concerns. Benefit-risk profile unchanged. | Drug: Temferon | Glioblastoma Multiforme | 25 | 2019-03-05 | 2026-05-27actual | — | 2026-06-11 |
| CELU | Celularity Incorporated | $21M | CYNK-001 IV and IC in Combination With IL2 in Surgical Eligible Recurrent GBM With IDH-1 Wild TypeNCT05218408Phase I-Number of patients experience Dose limiting toxicity (DLT) | Phase 1/2 | Withdrawnsponsor's stated reason: No participants were enrolled. Study was withdrawn prior to treatment initiation. | Biological: CYNK-001 systemic and Intra cavity administration | Astrocytoma, Grade IV, Glioblastoma, Giant Cell Glioblastoma, Glioblastoma Multiforme | 0 | Sep 2021 | 2021-10-23actual | — | 2026-06-08 |
| INO | Inovio Pharmaceuticals | $124M | INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM)NCT03491683Percentage of Participants with Adverse Events (AEs) | Phase 1/2 | Active, not recruiting | Biological: INO-5401, INO-9012, Cemiplimab · Radiation: Radiation Therapy · Drug: Temozolomide | Glioblastoma | 52 | 2018-05-31 | 2026-12-31 | in 133 d | 2026-05-04 |
| LTRN | Lantern Pharma Inc. | $32M | Study of LP-184 in Patients With Advanced Solid TumorsNCT05933265To evaluate the safety and tolerability of LP-184 assessed by the incidence and severity of all adverse events graded by CTCAE v5.0 | Phase 1/2 | Active, not recruiting | Drug: LP-184, Olaparib, Nivolumab & Ipilimumab | Advanced Solid Tumor, Metastatic Solid Tumor, GBM, TNBC - Triple-Negative Breast Cancer, NSCLC, Pancreatic Adenocarcinoma, DDR Gene Mutation | 64 | 2023-06-09 | 2026-07-28 | — | 2026-05-04 |
| BNTX | BioNTech SE | — | A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent GlioblastomaNCT07297212Confirmed overall response rate (ORR) | Phase 2 | Recruiting | Drug: Pumitamig, Bevacizumab, Temozolomide | Recurrent Glioblastoma | 75 | 2026-01-15 | Jan 2028 | ≤ 529 d | 2026-04-29 |
| PHIL.MI | Philogen S.p.A. | $1.1B | A Study With L19TNF in Combination With Lomustine in Patients With Glioblastoma at Progression or RecurrenceNCT06336291Adverse Events | Phase 2 | Active, not recruiting | Drug: L19TNF, L19TNF, L19TNF, Lomustine, Lomustine | Glioblastoma | 90 | 2024-05-22 | Jun 2026 | — | 2026-04-21 |
| NVCR | NovoCure Ltd. | $2.0B | Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant With RT & TMZ for the Treatment of Newly Diagnosed GBMNCT04471844Overall Survival (OS) | Not applicable | Completed | Device: Optune® | Glioblastoma Multiforme | 981 | 2020-12-08 | 2026-02-19actual | — | 2026-03-30 |
| INCY | Incyte Corporation | $24.7B | Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 AlterationsNCT05267106results2025-12-30Objective Response Rate (ORR) in Participants With Recurrent Glioblastoma Based on Independent Central Review | Phase 2 | Terminatedsponsor's stated reason: Recruitment ceased after a pre-planned futility interim analysis indicated a low probability to confer a clinically meaningful improvement in objective response when compared to currently available therapies. There were no safety related concerns. | Drug: Pemigatinib | Glioblastoma, Adult-type Diffuse Gliomas | 83 | 2022-05-20 | 2024-12-17actual | — | 2025-12-30 |
| JAZZ | Jazz Pharmaceuticals | $16.4B | Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System NeoplasmsNCT04541082Maximum Tolerated Dose (MTD) of single-agent, oral ONC206 | Phase 1 | Recruiting | Drug: ONC206 | Central Nervous System Neoplasms, Glioblastoma, Gliosarcoma, Adult, Anaplastic Oligodendroglioma, Anaplastic Astrocytoma, Pilocytic Astrocytoma, Oligodendroglioma, Gliomatosis Cerebri, Pleomorphic Xanthoastrocytoma, Anaplastic Pleomorphic Xanthoastrocytoma, Diffuse Midline Glioma, H3 K27M-Mutant, Ependymoma, Ependymoma, Anaplastic, Medulloblastoma, Teratoid Rhabdoid Tumor, Neuroectodermal Tumors, Primitive, Neuroectodermal Tumors, Anaplastic Meningioma, Atypical Meningioma, Choroid Plexus Neoplasms, Pineal Tumor, Diffuse Astrocytoma, Glial Tumor | 102 | 2020-10-26 | Jul 2026 | — | 2025-12-18 |
| LLY | Eli Lilly and Company | $1.15T | A Study in Recurrent Glioblastoma (GB)NCT01582269results2025-11-24Overall Survival (OS) | Phase 2 | Completed | Drug: Galunisertib, Lomustine, Placebo | Glioblastoma | 158 | 2012-04-26 | 2014-07-26actual | — | 2025-11-24 |
| TCRT | Alaunos Therapeutics | $5M | Evaluation of Ad-RTS-hIL-12 + Veledimex in Subjects With Recurrent or Progressive Glioblastoma, a Substudy to ATI001-102NCT03679754results2025-08-28Safety of Intratumoral Ad-RTS-hIL-12 and Oral Veledimex in Subjects With Recurrent or Progressive Glioblastoma Based on Evaluation of Adverse Events Summarized by Incidence, Intensity and Type of Adverse Event. | Phase 1 | Completed | Biological: Ad-RTS-hIL-12 · Drug: veledimex | Glioblastoma | 36 | 2018-09-05 | 2019-04-02actual | — | 2025-08-28 |
| PII | Polaris Group | $3.8B | ADI-PEG 20 Plus Radiotherapy and Temozolomide in Subjects With Glioblastoma MultiformeNCT04587830Overall survival (OS) | Phase 2 | Active, not recruiting | Drug: ADI-PEG 20, Temozolomide, Placebo | Glioblastoma Multiforme (GBM) | 100 | 2020-09-14 | 2027-02-28 | in 192 d | 2025-08-26 |
| INCY | Incyte Corporation | $24.7B | A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)NCT02327078results2023-04-26Phase 1, Part 1: Number of Participants With Dose Limiting Toxicities (DLTs) | Phase 1/2 | Completed | Drug: Nivolumab, Epacadostat, Chemotherapy | B-cell Malignancies, Colorectal Cancer (CRC), Head and Neck Cancer, Lung Cancer, Lymphoma, Melanoma, Ovarian Cancer, Glioblastoma | 307 | 2014-11-26 | 2020-06-16actual | — | 2025-08-14 |
| TCRT | Alaunos Therapeutics | $5M | A Study of Ad-RTS-hIL-12 With Veledimex in Combination With Nivolumab in Subjects With Glioblastoma; a Substudy to ATI001-102NCT03636477results2025-08-12Number of Participants With Adverse Events (AEs) | Phase 1 | Completed | Biological: Ad-RTS-hIL-12 · Drug: veledimex, Nivolumab | Glioblastoma | 21 | 2018-06-18 | 2020-10-15actual | — | 2025-08-12 |
| MNOV | MediciNova | $66M | Study to Evaluate Ibudilast and TMZ Combo Treatment in Newly Diagnosed and Recurrent GlioblastomaNCT03782415Evaluate safety and tolerability of ibudilast and temozolomide combination treatment | Phase 1/2 | Completed | Drug: MN-166, Temozolomide | Glioblastoma, Recurrent Glioblastoma, GBM, Newly Diagnosed Glioblastoma | 64 | 2018-12-29 | 2023-08-07actual | — | 2025-05-21 |
| INAB | In8bio Inc. | $11M | A Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide in Subjects With Recurrent or Newly Diagnosed GlioblastomaNCT05664243Autologous Phase 2, Arm A in newly diagnosed glioblastoma: 12-month overall survival (OS) rate | Phase 1/2 | Active, not recruiting | Biological: Autologous genetically modified gamma-delta T cells, Allogeneic genetically modified gamma-delta T cells | Glioblastoma | 4 | 2023-09-08 | Dec 2025 | — | 2025-05-01 |
| TCRT | Alaunos Therapeutics | $5M | Study of Ad-RTS-hIL-12 + Veledimex in Combination With Cemiplimab in Subjects With Recurrent or Progressive GlioblastomaNCT04006119results2025-04-18Safety of Intratumoral Ad-RTS-hIL-12 and Oral Veledimex in Combination With Cemiplimab-rwlc in Subjects With Recurrent or Progressive Glioblastoma. | Phase 2 | Terminatedsponsor's stated reason: Sponsor Decision | Biological: Ad-RTS-hIL-12 · Drug: Veledimex, Cemiplimab-Rwlc | Glioblastoma | 40 | 2019-08-01 | 2021-08-05actual | — | 2025-04-18 |
| TCRT | Alaunos Therapeutics | $5M | A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Glioblastoma or Malignant GliomaNCT02026271results2025-04-16Safety and Tolerability of Varying Doses of Intratumoral Ad-RTS-hIL-12 and Oral Veledimex Doses in Subjects With Recurrent or Progressive Glioblastoma or Grade III Malignant Glioma | Phase 1 | Completed | Biological: Ad-RTS-hIL-12 · Drug: veledimex | Glioblastoma Multiforme, Anaplastic Oligoastrocytoma | 40 | Jun 2015 | Aug 2019actual | — | 2025-04-16 |
| NVCR | NovoCure Ltd. | $2.0B | TTFields General Routine Clinical Care in ndGBM Patients: a French Prospective Non-Interventional Study (TIGER France)NCT06924099observationalOverall Survival (OS) | — | Recruiting | — | Glioblastoma | 430 | 2024-01-11 | 2029-01-31 | in 895 d | 2025-04-11 |
| BMY | Bristol-Myers Squibb | $134.9B | A Study of the Effectiveness and Safety of Nivolumab Compared to Bevacizumab and of Nivolumab With or Without Ipilimumab in Glioblastoma PatientsNCT02017717results2022-06-29Percentage of Participants With Drug-Related Adverse Events Leading to Discontinuation by Worst CTC Grade for All Treated Participants in Cohorts 1, 1b, 1c and 1d Who Permanently Discontinued Study Medication Prior to Completing Four Doses | Phase 3 | Completed | Biological: Nivolumab, Bevacizumab, Ipilimumab | Recurrent Glioblastoma | 529 | 2014-02-07 | 2019-06-17actual | — | 2025-04-04 |
| BDRX | Biodexa Pharmaceuticals | — | A Study of Intra-tumoral Administered MTX110 in Patients With Recurrent GlioblastomaNCT05324501Safety of MTX110 administered by CED | Phase 1 | Terminatedsponsor's stated reason: Strategic decision | Drug: MTX110 · Device: Programmable pump and catheter system | Recurrent Glioblastoma | 4 | 2022-10-19 | 2024-09-10actual | — | 2025-02-10 |
| JAZZ | Jazz Pharmaceuticals | $16.4B | Oral ONC201 in Adult Recurrent GlioblastomaNCT02525692results2024-12-24Percent of Patients With Probability of Progression-Free Survival at 6 Months | Phase 2 | Terminatedsponsor's stated reason: The Sponsor terminated the study to prioritize enrollment in a randomized Phase 3 trial of ONC201 in an earlier setting. This decision was unrelated to any safety concerns with dordaviprone (ONC201). | Drug: Dordaviprone (ONC201) | Glioblastoma, Diffuse Midline Glioma, H3 K27M Glioma, Thalamic Glioma, Infratentorial Glioma, Basal Ganglia Glioma | 84 | Jan 2016 | 2023-04-17actual | — | 2024-12-24 |
| KPTI | Karyopharm Therapeutics Inc | $44M | A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent GlioblastomaNCT04421378results2024-12-16Phase 1a and 1b: Maximum Tolerated Dose of Selinexor | Phase 1/2 | Terminatedsponsor's stated reason: Upon further consideration of the existing data and the competitive landscape, Karyopharm Therapeutics Inc has decided not to pursue the ongoing development of Selinexor in GBM at this time. | Drug: Selinexor, Temozolomide (TMZ), Lomustine (CCNU), Bevacizumab, Carmustine · Radiation: Standard Fractionated Radiation therapy (RT) · Device: TTField | Glioblastoma Multiforme | 74 | 2020-06-08 | 2023-07-03actual | — | 2024-12-16 |
| PRLD | Prelude Therapeutics | $459M | A Study of PRT3645 in Participants With Select Advanced or Metastatic Solid TumorsNCT05538572Dose limiting toxicity (DLT) of PRT3645 | Phase 1 | Completed | Drug: PRT3645 | Breast Cancer, Glioblastoma, Head and Neck Squamous Cell Carcinoma, Malignant Mesothelioma, Non-small Cell Lung Cancers, Sarcoma, Endometrial Cancer | 22 | 2022-12-27 | 2024-06-26actual | — | 2024-07-01 |
| IBRX | ImmunityBio, Inc. | $8.2B | Phase 2 Study to Investigate the Efficacy and Safety of Aldoxorubicin in Subjects With GlioblastomaNCT02014844results2024-05-29Objective Response Rate (Complete Response and Partial Response) | Phase 2 | Completed | Drug: 250 mg/m2 aldoxorubicin, 350 mg/m2 aldoxorubicin | Glioblastoma | 28 | Mar 2014 | Dec 2016actual | — | 2024-05-29 |
| 4151.T | Kyowa Kirin, Inc. | $8.4B | Expanded Access for KHK2455NCT04321694expanded access | — | No longer available | Drug: KHK2455 | Glioblastoma Multiforme | — | — | — | — | 2024-04-25 |
| PHIL.MI | Philogen S.p.A. | $1.1B | A Study to Evaluate Safety and Efficacy of L19TNF Plus Lomustine in Patients With Glioblastoma at First ProgressionNCT04573192For Phase 1: DLT | Phase 1/2 | Unknown status | Drug: L19TNF, Lomustine | Glioblastoma | 142 | 2021-02-19 | Mar 2025 | — | 2024-04-08 |
| PHIL.MI | Philogen S.p.A. | $1.1B | Safety and Efficacy of Different Administration Sequences of L19TNF With Lomustine in Glioblastoma at First ProgressionNCT05304663Safety of L19TNF plus lomustine with different administration sequences | Phase 1 | Withdrawnsponsor's stated reason: The Sponsor had no further plan for the study in object | Drug: Onfekafusp alfa, Lomustine | Glioblastoma | 0 | 2022-06-01 | 2024-12-31 | — | 2024-04-08 |
| CADL | Candel Therapeutics, Inc. | $922M | Phase 2a Study of CAN-2409 With Standard Radiation Therapy for Malignant GliomaNCT00589875results2024-04-03Number of Participants With Treatment Related Adverse Events | Phase 2 | Completed | Biological: CAN-2409 · Drug: Valacyclovir, Temozolomide · Radiation: Radiation therapy | Malignant Glioma, Glioblastoma Multiforme, Anaplastic Astrocytoma, High Grade Glioma | 52 | Mar 2007 | Dec 2015actual | — | 2024-04-03 |
| EXEL | Exelixis | $13.2B | Study of XL184 (Cabozantinib) in Adults With Glioblastoma MultiformeNCT00704288results2024-02-05Objective Response Rate (ORR) | Phase 2 | Completed | Drug: XL184 | Glioblastoma Multiforme | 222 | May 2008 | Jun 2012actual | — | 2024-02-05 |
| PHIL.MI | Philogen S.p.A. | $1.1B | Safety and Efficacy of L19TNF Plus Temozolomide Chemoradiotherapy in Patients With Newly Diagnosed GlioblastomaNCT04443010For Phase 1: DLT | Phase 1/2 | Recruiting | Drug: Onfekafusp alfa, Temozolomide | Glioblastoma | 226 | 2021-01-20 | Oct 2026 | ≤ 72 d | 2023-10-10 |
| CADL | Candel Therapeutics, Inc. | $922M | Phase 1b Study of AdV-tk + Valacyclovir Combined With Radiation Therapy for Malignant GliomasNCT00751270Incidence of treatment emergent adverse events | Phase 1 | Completed | Biological: AdV-tk · Drug: Valacyclovir | Malignant Glioma, Glioblastoma Multiforme, Anaplastic Astrocytoma | 15 | Nov 2005 | Jan 2010actual | — | 2023-08-25 |
| NUVB | Nuvation Bio Inc. | $2.4B | Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid TumorsNCT04541225Phase 1 Dose Escalation: Safety and tolerability of NUV-422 to determine the recommended Phase 2 dose (RP2D) | Phase 1 | Terminatedsponsor's stated reason: Sponsor decision | Drug: NUV-422 | Glioma, Glioma, Malignant, Glioma, Mixed, Glial Cell Tumors, Breast Cancer, Breast Carcinoma, Cancer of Breast, Cancer of the Breast, Breast Tumor, Malignant Tumor of Breast, Advanced Breast Cancer, Advanced Breast Carcinoma, Metastatic Breast Cancer, Metastatic Breast Carcinoma, Prostate Cancer, Prostatic Cancer, Cancer of Prostate, Cancer of the Prostate, Prostate Neoplasm, Castrate Resistant Prostate Cancer, Castration-resistant Prostate Cancer, Castration Resistant Prostatic Neoplasms, Glioblastoma, Recurrent Glioblastoma | 74 | 2020-12-08 | 2022-08-31actual | — | 2023-07-14 |
| ABBV | AbbVie | $457.5B | A Study of ABT-414 in Participants With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) AmplificationNCT02573324results2023-05-11Overall Survival (OS) | Phase 3 | Completed | Drug: Temozolomide, Depatuxizumab mafodotin, Placebo for ABT-414 · Radiation | Glioblastoma, Gliosarcoma | 691 | 2015-01-04 | 2022-04-04actual | — | 2023-05-11 |
| KPTI | Karyopharm Therapeutics Inc | $44M | Study Evaluating the Efficacy and Safety of Selinexor (KPT-330) in Participants With Recurrent GliomasNCT01986348results2021-08-026-Month Progression-Free Survival (PFS) Rate | Phase 2 | Terminatedsponsor's stated reason: Study was terminated due to Sponsor decision (all except 1 patient were off-treatment and 2 patients were in survival follow-up) | Drug: Selinexor | Glioblastoma, Glioma | 76 | 2014-03-03 | 2020-01-23actual | — | 2023-01-26 |
| NVCR | NovoCure Ltd. | $2.0B | TIGER PRO-Active - Daily Activity, Sleep and Neurocognitive Functioning StudyNCT04717739observationalTime of usage of TTFields treatment in follow-up derived from monitoring data of the devices, standardised to usage days, as measure of compliance with TTFields treatment. | — | Unknown status | Device: TTFields | Glioblastoma | 500 | 2021-12-30 | 2024-12-01 | — | 2023-01-10 |
| MDNAF | Medicenna Therapeutics, Inc. | $22M | Convection-Enhanced Delivery (CED) of MDNA55 in Adults With Recurrent or Progressive GlioblastomaNCT02858895results2022-10-24Overall Survival (OS) | Phase 2 | Completed | Drug: MDNA55 | Glioblastoma, Grade IV Astrocytoma, Glioblastoma Multiforme, Grade IV Glioma | 47 | 2017-04-11 | 2019-09-12actual | — | 2022-10-24 |
| SNY | Sanofi | — | Study of the Poly (ADP-ribose) Polymerase-1 (PARP-1) Inhibitor BSI-201 in Patients With Newly Diagnosed Malignant GliomaNCT00687765To determine the Maximum Tolerated Dose (MTD) of BSI-201, administered as an IV infusion in patients with newly diagnosed malignant glioma when given with temozolomide (TMZ) after the completion of standard radiation therapy and concomitant TMZ | Phase 1/2 | Completed | Drug: bsi-201 plus temozolomide | Glioblastoma | 126 | Jul 2008 | Jun 2015actual | — | 2022-09-14 |
| CELU | Celularity Incorporated | $21M | Natural Killer Cell (CYNK-001) IV Infusion or IT Administration in Adults With Recurrent GBMNCT04489420Number of Participants who experienced a Dose-Limiting Toxicity (DLT) | Phase 1 | Terminatedsponsor's stated reason: Business decision. | Biological: CYNK001-IV, CYNK001-IT | Astrocytoma, Grade IV, Giant Cell Glioblastoma, Glioblastoma Multiforme, Cyclophosphamide, Immunosuppressive Agents, Immunologic Factors, Physiological Effects of Drugs, Molecular Mechanisms of Pharmacological Action, Antiviral Agents, Anti-infective Agents, Analgesics, Non-narcotic, Analgesics, Sensory System Agents, Peripheral Nervous System Agents | 3 | 2020-10-01 | 2021-08-10actual | — | 2022-08-10 |
| BSX | Boston Scientific Corporation | $73.1B | A Phase 1 / 2 Dose Escalation Study of Locally-Administered OncoGel™ in Subjects With Recurrent GliomaNCT00479765results2014-05-15Occurence of Dose-limiting Toxicities (DLTs) | Phase 1/2 | Terminatedsponsor's stated reason: Sponsor business decision, not based on safety or efficacy data | Drug: OncoGel (ReGel/Paclitaxel) | Glioblastoma Multiforme, Brain Neoplasms | 4 | Mar 2007 | Oct 2009actual | — | 2022-06-22 |
| NWBO | Northwest Biotherapeutics | $301M | Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain CancerNCT00045968The primary objective of this study is to compare overall survival (OS) between patients randomized to DCVax-L and control patients from comparable, contemporaneous trials who received standard of care therapy only, in newly diagnosed glioblastoma. | Phase 3 | Unknown status | Drug: Dendritic cell immunotherapy | Glioblastoma Multiforme, Glioblastoma, GBM, Grade IV Astrocytoma, Glioma, Brain Cancer, Brain Tumor | 348 | Dec 2006 | Nov 2022 | — | 2022-05-18 |
| GILD | Gilead Sciences | $177.9B | Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial CancerNCT01631552results2021-04-06Percentage of Participants Experiencing Any Treatment Emergent Adverse Events and Serious Treatment Emergent Adverse Events | Phase 1/2 | Completed | Drug: Sacituzumab Govitecan-hziy (SG) | Gastric Adenocarcinoma, Esophageal Cancer, Hepatocellular Carcinoma, Non-small Cell Lung Cancer, Small Cell Lung Cancer, Ovarian Epithelial Cancer, Carcinoma Breast Stage IV, Hormone-refractory Prostate Cancer, Head and Neck Cancers- Squamous Cell, Renal Cell Cancer, Urinary Bladder Neoplasms, Cervical Cancer, Endometrial Cancer, Glioblastoma Multiforme, Triple Negative Breast Cancer, Pancreatic Cancer | 515 | 2012-12-17 | 2019-03-01actual | — | 2021-08-12 |
| ABBV | AbbVie | $457.5B | UNITE Study: Understanding New Interventions With GBM ThErapyNCT03419403results2021-04-14Percentage of Participants Who Required a Change in Ocular Side Effect (OSE) Management | Phase 3 | Terminatedsponsor's stated reason: The study was terminated because clinical development of depatuxizumab mafodotin in glioblastoma was stopped due to lack of survival benefit. | Drug: Steroid eye drops, Vasoconstrictor eye drops, Ophthalmic steroid ointment, Depatuxizumab mafodotin, Temozolomide · Other: Cold compress · Radiation | Glioblastoma Multiforme | 40 | 2018-07-30 | 2019-09-05actual | — | 2021-04-14 |
| NVCR | NovoCure Ltd. | $2.0B | TTFields In GErmany in Routine Clinical CareNCT03258021observationalTime to death of any cause (overall survival (OS)) from diagnosis | — | Unknown status | Device: TTFields | Glioblastoma | 710 | 2017-08-31 | Jun 2021 | — | 2021-01-28 |
| BIIB | Biogen | $31.4B | Dose Escalation Study to Determine the Safety of IFN-Beta Gene Transfer in the Treatment of Grade III & Grade IV GliomasNCT00031083 | Phase 1 | Completed | Genetic: Interferon-beta | Glioblastoma Multiforme, Anaplastic Astrocytoma, Oligoastrocytoma, Mixed, Gliosarcoma | 12 | 2002-04-02 | — | — | 2020-11-17 |
| ABBV | AbbVie | $457.5B | Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid TumorsNCT02709889results2020-10-19Summary of Treatment-Emergent Adverse Events (TEAEs), by Dose and Neuroendocrine (NEC) or Non-NEC Disease Groups | Phase 1/2 | Terminatedsponsor's stated reason: Strategic considerations | Drug: Rovalpituzumab tesirine, Dexamethasone | Malignant Melanoma, Medullary Thyroid Cancer, Glioblastoma, Large-Cell Neuroendocrine Carcinoma, Neuroendocrine Prostate Cancer, High Grade Gastroenteropancreatic Neuroendocrine Carcinoma, Other Neuroendocrine Carcinoma, Other Solid Tumors | 200 | 2016-09-23 | 2019-08-27actual | — | 2020-10-19 |
| LLY | Eli Lilly and Company | $1.15T | Trial of Enzastaurin and Bevacizumab in Participants With Recurrent Malignant GliomasNCT00586508results2020-09-24Progression-Free Survival at 6 Months (PFS-6) | Phase 2 | Completed | Drug: enzastaurin, bevacizumab, Enzyme-inducing antiepileptic drugs (EIAED), Non-enzyme inducing antiepileptic drugs (NEIAED) | Recurrent Glioblastoma | 81 | Nov 2007 | Oct 2013actual | — | 2020-09-24 |
| ABBV | AbbVie | $457.5B | Study Evaluating ABT-414 in Japanese Subjects With Malignant GliomaNCT02590263Percentage of participants with adverse events | Phase 1/2 | Completed | Radiation: Whole Brain Radiation · Drug: Temozolomide, ABT-414 | Malignant Glioma, Glioblastoma Multiforme | 53 | 2015-08-24 | 2020-08-27actual | — | 2020-09-03 |
| LLY | Eli Lilly and Company | $1.15T | Phase 1/2 Study of Enzastaurin in Newly Diagnosed Glioblastoma Multiforme (GBM) and Gliosarcoma (GS) PatientsNCT00402116results2020-08-06Phase 1- Determination of the Maximum Tolerated Dose (MTD) of Enzastaurin | Phase 1/2 | Completed | Drug: enzastaurin, temozolomide · Radiation: radiation therapy | Glioblastoma, Glioblastoma Multiforme, Gliosarcoma | 72 | Sep 2006 | Dec 2009actual | — | 2020-08-06 |
| ABBV | AbbVie | $457.5B | Adult Study: ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma Pediatric Study: Evaluation of ABT-414 in Children With High Grade GliomasNCT02343406results2020-05-22Adult Study: Overall Survival (OS) | Phase 2 | Completed | Drug: Depatuxizumab mafodotin, Temozolomide, Lomustine | Glioblastoma | 266 | 2015-02-17 | 2019-06-24actual | — | 2020-05-22 |
| 4568.T | Daiichi Sankyo | $31.7B | A Phase 2 Study of PLX3397 in Patients With Recurrent GlioblastomaNCT01349036results2020-01-09Summary of Response Rates in Participants on Treatment With PLX3397 | Phase 2 | Terminatedsponsor's stated reason: Business Decision | Drug: PLX3397 | Recurrent Glioblastoma | 38 | 2011-12-03 | 2013-11-05actual | — | 2020-03-03 |
| CLDX | Celldex Therapeutics | $3.3B | A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive GlioblastomaNCT01498328Groups 1 and 2: Progression-free survival rate | Phase 2 | Completed | Drug: Bevacizumab, Rindopepimut (CDX-110) with GM-CSF, KLH | Glioblastoma, Small Cell Glioblastoma, Giant Cell Glioblastoma, Gliosarcoma, Glioblastoma With Oligodendroglial Component, Recurrent Glioblastoma, Relapsed Glioblastoma | 127 | Dec 2011 | Apr 2015actual | — | 2020-02-17 |
| LLY | Eli Lilly and Company | $1.15T | Enzastaurin Versus Lomustine in GlioblastomaNCT00295815The primary objective is to compare Enzastaurin versus Lomustine in patients who for the second time have brain cancer (specifically intracranial glioblastoma) to see what effect the drugs have on keeping the disease from progressing (worsening). | Phase 3 | Completed | Drug: enzastaurin, lomustine | Glioblastoma | 397 | Jan 2006 | Aug 2007actual | — | 2019-09-12 |
| LLY | Eli Lilly and Company | $1.15T | Enzastaurin Before and Concomitant With Radiation, Followed by Enzastaurin in Participants With Newly Diagnosed GlioblastomaNCT00509821results2019-04-05Percentage of Participants With Progression Free Survival at 6 Months (PFS-6) | Phase 2 | Completed | Drug: Enzastaurin 500 milligram (mg) Once Daily (QD), Enzastaurin 250 mg Twice Daily (BID) | Glioblastoma Multiforme | 60 | Oct 2007 | Feb 2010actual | — | 2019-04-05 |
| NVCR | NovoCure Ltd. | $2.0B | TTFields Together With Temozolomide and Radiotherapy in Patients With Newly Diagnosed GBMNCT03780569Safety of concomitant Radiotherapy/Temozolomide with NovoTTF-200A: The incidence of Radiotherapy treatment delays during concomitant Radiotherapy/Temozolomide/NovoTTF-200A will be documented including severity and relationship to NovoTTF-200A. | Not applicable | Unknown status | Device: NovoTTF-200A · Radiation: Radiotherapy · Drug: Temozolomide | Glioblastoma Multiforme | 10 | 2017-04-27 | Jan 2019 | — | 2018-12-20 |
| ABBV | AbbVie | $457.5B | A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor ReceptorNCT02365662Number of participants with adverse events | Phase 1 | Terminatedsponsor's stated reason: Safety | Drug: ABBV-221 | Head and Neck Squamous Cell Carcinoma, Non-small Cell Lung Cancer, Triple Negative Breast Cancer, Colorectal Carcinoma, Glioblastoma Multiforme | 46 | 2015-01-09 | 2018-03-15actual | — | 2018-03-30 |
| CLDX | Celldex Therapeutics | $3.3B | Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed GlioblastomaNCT01480479Overall Survival | Phase 3 | Completed | Drug: Rindopepimut (CDX-110) with GM-CSF, Temozolomide, KLH | Glioblastoma, Small Cell Glioblastoma, Giant Cell Glioblastoma, Gliosarcoma, Glioblastoma With Oligodendroglial Component | 745 | Nov 2011 | Nov 2016actual | — | 2018-01-16 |
| ABBV | AbbVie | $457.5B | Evaluating the Safety and Pharmacokinetics of ABT-414 for Subjects With Glioblastoma MultiformeNCT01800695Number and percentage of participants with adverse events | Phase 1 | Completed | Drug: ABT-414, Temozolomide · Radiation: Whole Brain Radiation | Glioblastoma Multiforme | 202 | 2013-04-02 | 2017-06-19actual | — | 2017-11-21 |
| NVCR | NovoCure Ltd. | $2.0B | Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM)NCT00916409Progression Free Survival (PFS) time | Phase 3 | Completed | Device: NovoTTF-100A device · Drug: Temozolomide | Glioblastoma Multiforme | 700 | Jun 2009 | Dec 2016actual | — | 2017-04-10 |
| NVS | Novartis | — | Open-label Trial of Imatinib Mesylate in Patients With Unresectable Recurrent Glioblastoma Multiforme Expressing PDGFR (Platelet Derived Growth Factor Receptors)NCT00171938PFS (progression free-survival), defined by the percentage of patients without evidence of progressive disease in 6 months | Phase 2 | Terminated | Drug: imatinib mesylate | Glioblastoma | 30 | Apr 2004 | Jun 2006actual | — | 2017-02-24 |
| AZN | AstraZeneca | — | Cediranib in Combination With Lomustine Chemotherapy in Recurrent GlioblastomaNCT00777153results2012-12-21Progression Free Survival (PFS) | Phase 3 | Completed | Drug: Cediranib, Cediranib, Lomustine Chemotherapy, Placebo Cediranib | Recurrent Glioblastoma | 423 | Oct 2008 | Apr 2010actual | — | 2016-12-28 |
| AMGN | Amgen | $229.9B | AMG 595 First-in-Human in Recurrent GliomasNCT01475006Clinically significant or > or = to Grade 3 CTCAE changes in safety laboratory tests, physical exams, ECGs or vital signs | Phase 1 | Completed | Drug: AMG 595 | Advanced Malignant Glioma, Anaplastic Astrocytomas, Glioblastoma Multiforme | 32 | Feb 2012 | Apr 2016actual | — | 2016-04-15 |
| NVCR | NovoCure Ltd. | $2.0B | Post-approval Study of NovoTTF-100A in Recurrent GBM PatientsNCT01756729Overall Survival | Phase 4 | Terminatedsponsor's stated reason: Amendment of Study Protocol | Device: NovoTTF-100A | Recurrent Glioblastoma Multiforme | 13 | Dec 2012 | Jan 2018 | — | 2016-03-02 |
| NWBO | Northwest Biotherapeutics | $301M | Expanded Access Protocol for GBM Patients With Already Manufactured DCVax®-L Who Have Screen-Failed Protocol 020221NCT02146066expanded access | — | Available | Biological: DCVax-L | GBM, Glioblastoma Multiforme | — | — | — | — | 2016-02-26 |
| CLRB | Cellectar Biosciences, Inc. | $24M | Imaging Trial With I-124-CLR1404 in Patients With Newly Diagnosed or Recurrent GlioblastomaNCT01898273Optimal Imaging Parameters - Dose | Phase 2 | Terminated | Drug: I-124-CLR1404 | Glioblastoma | 7 | Feb 2014 | Sep 2015 | — | 2015-09-09 |
| PFE | Pfizer | $155.3B | A Trial Of PF-04856884 In Patients With Recurrent GlioblastomaNCT01225510Progression free survival rate at Month 6 (PFS6) defined as the patient progression free status at Month 6. | Phase 2 | Withdrawn | Biological: PF-04856884, PF-04856884 | Glioblastoma | 0 | Jan 2011 | Jan 2013 | — | 2015-03-11 |
| EXEL | Exelixis | $13.2B | Safety Study of XL184 (Cabozantinib) in Combination With Temozolomide and Radiation Therapy in the Initial Treatment of Adults With GlioblastomaNCT00960492Evaluate the safety and tolerability of oral administration of XL184 added to first-line treatment for subjects with newly diagnosed GB | Phase 1 | Completed | Drug: XL184, temozolomide, temozolomide, temozolomide · Radiation: Radiation Therapy | Glioblastoma, Giant Cell Glioblastoma, Gliosarcoma | 26 | Sep 2009 | Nov 2012actual | — | 2014-09-22 |
| GILD | Gilead Sciences | $177.9B | Efficacy Study of CYT997 in Combination With Carboplatin in GlioblastomaNCT00650949Safety and tolerability of escalating doses of CYT997 when given in combination with standard carboplatin therapy (Phase Ib component) | Phase 1/2 | Terminatedsponsor's stated reason: Strategic | Drug: CYT997, Carboplatin | Glioblastoma Multiforme | 20 | Nov 2009 | Jun 2011actual | — | 2013-05-03 |
| SNY | Sanofi | — | A Study of XL765 (SAR245409) in Combination With Temozolomide With and Without Radiation in Adults With Malignant GliomasNCT00704080Safety, tolerability, and maximum tolerated dose of XL765 administered in combination with temozolomide in subjects with anaplastic gliomas or glioblastoma currently stable on a maintenance temozolomide dose | Phase 1 | Completed | Drug: XL765 (SAR245409), Temozolomide | Mixed Gliomas, Malignant Gliomas, Glioblastoma Multiforme | 54 | Aug 2008 | Feb 2012actual | — | 2013-04-10 |
| BMY | Bristol-Myers Squibb | $134.9B | Study of CCNU (Lomustine) Plus Dasatinib in Recurrent Glioblastoma (GBM)NCT00948389results2012-08-28Number of Participants With Adverse Events (AEs), Serious AEs (SAEs), Deaths, and Discontinuations Due to AEs | Phase 1/2 | Terminatedsponsor's stated reason: Inability to meet protocol objectives | Drug: Dasatinib, Lomustine | Glioblastoma | 28 | Oct 2009 | May 2011actual | — | 2012-08-31 |
| SNY | Sanofi | — | Exploratory Study of XL765 (SAR245409) or XL147 (SAR245408) in Subjects With Recurrent Glioblastoma Who Are Candidates for Surgical ResectionNCT01240460To explore the biological effect of XL765 and XL147 measured by modulation of PI3K/ mTOR pathway readouts in GB tumor tissue | Phase 1 | Completed | Drug: XL765 (SAR245409), XL147 (SAR245408) | Glioblastoma, Astrocytoma, Grade IV | 40 | Jan 2011 | Jun 2012actual | — | 2012-07-27 |
| NVCR | NovoCure Ltd. | $2.0B | Effect of NovoTTF-100A in Recurrent Glioblastoma Multiforme (GBM)NCT00379470Overall Survival | Phase 3 | Completed | Device: NovoTTF-100A | Recurrent Glioblastoma Multiforme | 236 | Sep 2006 | Nov 2009actual | — | 2012-05-01 |
| PFE | Pfizer | $155.3B | A Study Of Crizotinib Plus VEGF Inhibitor Combinations In Patients With Advanced Solid Tumors.NCT01441388Dose Limiting Toxicities (DLTs). | Phase 1 | Withdrawnsponsor's stated reason: Business/Operational issues | Drug: Crizotinib plus VEGF inhibitor combinations, Crizotinib plus axitinib, Crizotinib plus sunitinib, Crizotinib plus axitinib, Crizotinib plus sunitinib, Crizotinib plus bevacizumab, Crizotinib plus sorafenib | Carcinoma, Renal Cell, Glioblastoma, Carcinoma, Hepatocellular | 0 | Dec 2011 | Nov 2013 | — | 2011-12-20 |
| AZN | AstraZeneca | — | A Phase II Exploratory, Multicentre, Open-label, Non-comparative Study of ZD1839 (Iressa) and Radiotherapy in the Treatment of Patients With Glioblastoma MultiformeNCT00238797Objective tumour response at 6 months after the end of combination treatment by computerized tomography scan or magnetic resonance imaging of the brain according to Macdonald criteria. | Phase 2 | Completed | Drug: Gefitinib | Glioblastoma | 36 | Feb 2003 | — | — | 2011-01-21 |
| AZN | AstraZeneca | — | Phase I : Cediranib in Combination With Lomustine Chemotherapy in Recurrent Malignant Brain TumourNCT00503204Assess the safety and tolerability of cediranib in combination with oral lomustine and to confirm a dose for further studies with this combination. | Phase 1 | Completed | Drug: Cediranib, Lomustine | Recurrent Glioblastoma, Brain Tumor | 20 | Sep 2007 | Dec 2008actual | — | 2009-11-25 |
| PFE | Pfizer | $155.3B | Study of IV Edotecarin Vs Temozolomide or Carmustine (BCNU) or Lomustine (CCNU) in Patients With Glioblastoma MultiformeNCT00068952To compare the overall survival associated with edotecarin versus that associated with temozolomide or BCNU or CCNU for the treatment of patients with GBM at first relapse previously treated with alkylator-based (neo)adjuvant therapy | Phase 3 | Completed | Drug: Edotecarin, Temozolomide, Carmustine (BCNU), Lomustine (CCNU) | Glioblastoma | 118 | Aug 2003 | — | — | 2008-04-01 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
How Glioblastoma is matched — 10 exact registry spellings
A study is on this page when its ClinicalTrials.gov record names one of these conditions exactly (letter case aside). Nothing is matched by substring or stem, so a longer condition that merely contains one of these words is a different page. The list was curated by hand and last measured 2026-08-19; a spelling filed by only one study was not curated, so the counts here are a floor rather than the registry's own total for the disease.
- Glioblastoma
- Glioblastoma Multiforme
- Recurrent Glioblastoma
- GBM
- Giant Cell Glioblastoma
- Recurrent Glioblastoma Multiforme
- Glioblastoma Multiforme (GBM)
- Glioblastoma With Oligodendroglial Component
- Newly Diagnosed Glioblastoma
- Small Cell Glioblastoma
Permalink · All conditions · Catalyst calendar · Every registered study · Search the whole pipeline for “Glioblastoma” (a text search, wider than this page)